Empiric Therapy of Infections in Hematologic Malignancies: A Prospective, Randomized Trial

Patients with hematologic malignancies were randomly assigned to receive cefuroxime (group A) or tobramycin plus ampicillin (Group B) during 86 febrile episodes. In both regimens carbenicillin was added during neutropenia (71% of all episodes: groups C and D). The most common type of infection was pneumonia (48% alone; 72% with other sites involved), which accounted for a high fatality rate (15%); the highest rate occurred during septicemia with pneumonia (50%). The overall response rate to initial therapy was 63% without significant differences among the four regimens. The worst prognosis was observed in neutropenic patients without granulocyte recovery. When initial and cross-over trials were combined, there were favorable outcomes in 90% of all cases. Cefuroxime alone seems to be as effective as tobramycin plus ampicillin in the treatment of infections in hematologic malignancies. No side effects could be attributed to the cefuroxime-containing regimens.

[1]  A. Cortelezzi,et al.  Efficacy of the tobramycin - cotrimoxazole - cephalothin combination for febrile episodes in leukemic patients with granulocytopenia. , 1981, Haematologica.

[2]  P. Pizzo,et al.  The value of protective isolation in preventing nosocomial infections in high risk patients. , 1981, The American journal of medicine.

[3]  R. Stuart,et al.  Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. , 1980, The American journal of medicine.

[4]  W. R. Mccabe,et al.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. , 1980, The American journal of medicine.

[5]  B. Yap,et al.  Netilmicin in the treatment of infections in patients with cancer. , 1979, Archives of internal medicine.

[6]  G. Bodey,et al.  A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. , 1979, The American journal of medicine.

[7]  J. Bender,et al.  Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. , 1979, The American journal of medicine.

[8]  A. Hopefl.  Empiric therapy of febrile granulocytopenic patients. , 1979, American journal of hospital pharmacy.

[9]  S. Ketchel,et al.  Acute infections in cancer patients. , 1978, Seminars in oncology.

[10]  G. Bodey,et al.  Carbenicillin plus cefamandole in the treatment of infections in patients with cancer. , 1978, The Journal of infectious diseases.

[11]  J. Aisner,et al.  Empiric antibiotic therapy. , 1978, Cancer treatment reports.

[12]  G. Bodey,et al.  Fever and infection in leukemic patients. A study of 494 consecutive patients , 1978, Cancer.

[13]  J. Klastersky,et al.  Carbenicillin, cefazolin, and amikacin as an empiric therapy for febrile granulocytopenic cancer patients. , 1977, Cancer treatment reports.

[14]  G. Bodey.  Infectious complications in the cancer patient. , 1977, Current problems in cancer.

[15]  E. Freireich,et al.  CAUSES OF DEATH IN ADULTS WITH ACUTE LEUKEMIA , 1976, Medicine.

[16]  J. Klastersky.  Infections in cancer patients , 1982 .

[17]  J. Aubertin,et al.  Opportunistic infections in cancer patients , 1978 .

[18]  M. Tattersall,et al.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. , 1978, The Journal of infectious diseases.

[19]  R. Feld,et al.  Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer. , 1977, The Journal of infectious diseases.